SecBot SecBot
DEF 14A ·Filed Nov 5, 2026

NRXP

NRX Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 10h ago SEC0001437749-26-035303
Definitive proxy statement
Actionable Insight • Neutral

The DEFA14A filed concurrently signals a contested director election, which may lead to a proxy fight. Monitor for dissident filings and any shareholder proposals that could emerge before the December 17 meeting.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.38
T+0 close · Nov 5, 2026 · via day close
Latest settled
−7.98%
T+5 · $2.19
Vs SPY
−10.58%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $2.38entry
  2. T+1 · 8d ago 0.00%α −2.37% · $2.38
  3. T+5 · 4d ago −7.98%α −10.58% · $2.19
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRX Pharmaceuticals filed its definitive proxy statement for the 2026 annual meeting, seeking to elect Dennis McBride as the sole Class II director and ratify Weinberg & Company as auditors. The filing is routine but occurs alongside a DEFA14A filed the same day indicating a contested election, adding governance uncertainty.

Key Facts

  • Annual meeting scheduled for December 17, 2026, virtual-only format.
  • Only one director nominee: Dennis McBride for Class II.
  • Board has 5 directors, all male, all White; classified board with staggered three-year terms.
  • CEO Jonathan Javitt also serves as Chairman (combined role).
  • No shareholder proposals on the ballot.
  • Related party transactions: $0 paid to Glytech LLC (owned by CEO's brother) in 2025 vs $0.3M in 2024; $0.2M paid to CEO's son Zachary Javitt in 2025 vs $0.1M in 2024.
  • Auditor changed from Salberg & Company to Weinberg & Company effective November 20, 2025.
  • Total audit fees for 2025: $324,000 (Weinberg $150,000, Salberg $98,000, KPMG $0).
  • PEO total compensation 2025: $884,701 (CAP $1,042,201); net loss widened to $28.6M in 2025 from $25.1M in 2024.
  • 5%+ stockholder: B Group Capital LLC owns 6.9% (3,000,000 shares).
  • DEFA14A filed same day indicates proxy fight materials and contested election.

Financial Impact

Net loss increased 14% to $28.6M in 2025; PEO compensation actually paid rose 12% to $1.04M.

net lossexecutive compensation

Risk Factors

  • Contested election could distract management and increase costs.
  • Combined CEO/Chairman role and related party transactions raise governance concerns.
  • Widening net loss with rising executive compensation may attract shareholder dissent.
  • Low insider ownership (4.9% aggregate) limits alignment with minority holders.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001437749-26-035303
Document: 0001437749-26-035303-index-headers.html0001437749-26-035303
Document: 0001437749-26-035303-index.html0001437749-26-035303
Document: 0001437749-26-035303.txt0001437749-26-035303

Track record

22 reports on NRXP

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Viewing Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026